Table 1 Baseline Demographic and Disease Characteristics for Patients Who Provided BPI-SF or RSCL at Baseline
BPI-SF patients | RSCL patients | |
|---|---|---|
Number of patients with baseline assessment | 286 | 336 |
Age, median (range) | 55 (27–83) | 54 (27–83) |
Age ≥ 65 years (n, %) | 56 (19.6) | 59 (17.6) |
Ethnicity, n (%) | ||
Caucasian | 202 (70.6) | 220 (65.5) |
Asian | 15 (5.2) | 16 (4.8) |
Hispanic | 55 (19.2) | 86 (25.6) |
Other | 14 (4.9) | 14 (4.2) |
Stage at entry (n, %) | ||
Unresectable | 14 (4.9) | 15 (4.5) |
Metastatic | 272 (95.1) | 321 (95.5) |
Karnofsky Performance Status (n, %) | ||
< 90 | 75 (26.2) | 86 (25.6) |
90 or 100 | 210 (73.4) | 249 (74.1) |
Unknown | 1 (0.3) | 1 (0.3) |
Tumor metastatic site (n, %) | ||
Visceral | 213 (74.5) | 251 (74.7) |
Non-visceral only | 73 (25.5) | 85 (25.3) |
Menopausal status | ||
Peri-menopausal | 10 (3.6) | 12 (3.6) |
Post-menopausal | 237 (84.3) | 277 (83.7) |
Pre-menopausal | 34 (12.1) | 42 (12.7) |
Unknown | 5 (1.7) | 5 (1.5) |
Estrogen receptor status (n, %) | ||
Positive | 117 (40.9) | 133 (39.6) |
Negative | 120 (42.0) | 141 (42.0) |
Unknown | 49 (17.1) | 62 (18.5) |
Progesterone receptor status | ||
Positive | 101 (35.3) | 113 (33.6) |
Negative | 123 (43.0) | 146 (43.5) |
Unknown | 62 (21.7) | 77 (22.9) |
Pathologic diagnosis | ||
Ductal breast carcinoma | 228 (79.7) | 276 (82.1) |
Non-ductal breast carcinoma | 58 (20.3) | 60 (17.9) |
Basis for pathologic diagnosis | ||
Histopathological | 257 (89.9) | 303 (90.2) |
Cytological | 29 (10.1) | 33 (9.8) |
Prior radiotherapy | ||
Yes | 196 (68.5) | 238 (70.8) |
No | 90 (31.5) | 98 (29.2) |
Prior hormone therapy | ||
Yes | 151 (52.8) | 164 (48.8) |
No | 135 (47.2) | 172 (51.2) |